Gingival overgrowth in children: Epidemiology, pathogenesis, and complications. A literature review

Journal of Periodontology

Volumn 76, Issue 1, 2005, Pages 3-10

  Doufexi, Aikaterini ^a   Mina, Mina ^a   Ioannidou, Effie ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Fibromatosis, gingival complications; Fibromatosis, gingival epidemiology; Genetic diseases inborn; Gingival hyperplasia complications; Gingival hyperplasia epidemiology; Neurofibromatosis complications; Neurofibromatosis epidemiology

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; AMLODIPINE; ANTICONVULSIVE AGENT; AZATHIOPRINE; BEPRIDIL; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; COLLAGENASE; CYCLOSPORIN; DILTIAZEM; ETHOSUXIMIDE; ETHOTOIN; FELBAMATE; FELODIPINE; MATRIX METALLOPROTEINASE; MEPHENYTOIN; MESUXIMIDE; NIFEDIPINE; NIKETHAMIDE; NIMODIPINE; NITRENDIPINE; PHENOBARBITAL; PHENSUXIMIDE; PHENYTOIN; PREDNISOLONE; PRIMIDONE; TISSUE INHIBITOR OF METALLOPROTEINASE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

AGE; ANTIINFLAMMATORY ACTIVITY; AUTOSOMAL DOMINANT DISORDER; BRAIN ATROPHY; CELL COUNT; CHILD; CHILDHOOD DISEASE; CONNECTIVE TISSUE; DENTAL CARIES; DENTITION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENETIC HETEROGENEITY; GINGIVA FIBROMATOSIS; GINGIVA OVERGROWTH; HEADACHE; HODGKIN DISEASE; HUMAN; HYPERTENSION; LEUKEMIA; MALIGNANT TRANSFORMATION; MENTAL DEFICIENCY; MENTAL DISEASE; NEUROFIBROMA; NEUROFIBROMATOSIS; PATHOGENESIS; PREVALENCE; REVIEW; SEIZURE; SEX DIFFERENCE; SPEECH DISORDER; TOOTH DISEASE; TOOTH ERUPTION; TOOTH PLAQUE;

AGE FACTORS; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; FIBROMATOSIS, GINGIVAL; GINGIVAL OVERGROWTH; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEUROFIBROMATOSIS 1; SEX FACTORS; TOOTH MIGRATION;

EID: 15944403538     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2005.76.1.3     Document Type: Review

References (90)

1. Bokenkamp A, Bohnhorst B, Beier C, et al. Nifedipine aggravates cyclosporine A-induced hyperplasia. Pediatr Nephrol 1994;8:181-185.
2. Botha PJ. Drug induced gingival hyperplasia and its management - a literature review. J Dent Assoc S Afr 1997;52:659-664.
3. Brunet L, Miranda J, Farre M, Berini L, Mendieta C. Gingival enlargement induced by drugs. Drugs S Afr 1996; 15:219-231.
4. Butler RT, Kalkwarf KL, Kaldahl WB. Drug induced gingival hyperplasia: Phenytoin, cyclosporine and nifedipine. J Am Dent Assoc 1987;114:56-60.
5. Desai P, Silver JG. Drug-induced gingival enlargements J Can Dent Assoc 1998;64:263-268.
6. Dongari A, McDonnell HT, Langlais RP. Drug-induced gingival overgrowth. Oral Surg Oral Med Oral Pathol 1993;76:543-548.
7. Hassel TM, Hefti AF. Drug-induced gingival overgrowth: Old problem, new problem. Crit Rev Oral Biol Med 1991; 2:103-137.
8. Seymour RA. Calcium channel blockers and gingival overgrowth. Br Dent J 1991;170:376-379.
9. Seymour RA, Jacobs DJ. Cyclosporine and the gingival tissues. J Clin Periodontol 1992;19:1-11.
10. Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporine and nifedipine-induced gingival overgrowth. J Clin Periodontol 1993;20:37-40.
11. Seymour RA, Smith DG, Rogers SR. The comparative effects of azathioprine and cyclosporine on some gingival health parameters of renal transplant patients. Longitudinal study. J Clin Periodontol 1987;14:610-613.
12. Barclay S, Thomason JM, Idle JR, Seymour RA. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992;19:311-4.
13. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug induced gingival overgrowth. J Clin Periodontol 1996;23:165-175.
14. Hassell TM. Epilepsy and the oral manifestations of phenytoin therapy. Monogr Oral Sci 1981;9:1-205.
15. Hefti AF, Eshenaur AE, Hassell TM, Stone C. Gingival overgrowth in cyclosporine A treated multiple sclerosis patients. J Periodontol 1994;65:744-749.
16. Kitamura K, Morisaki I, Adachi C, et al. Gingival overgrowth induced by cyclosporine A in rats. Arch Oral Biol 1990;35:483-486.
17. Morisaki I, Kato K, Loyola -Rodriguez JP, Nagata T, Ishida H. Nifedipine-induced gingival overgrowth in the presence or absence of gingival inflammation in rats. J Periodontal Res 1993;28(Pt. 1):396-403.
18. Seymour RA, Ellis JS, Thomason JM. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000;27:217-223.
19. Allman SD, McWhorter AG, Seale NS. Evaluation of cyclosporine-induced gingival overgrowth in the pediatric transplant patient. Pediatr Dent 1994;16:36-40.
20. Karpinia KA, Matt M, Fennell RS 3rd, Hefti AF. Factors affecting cyclosporine-induced gingival overgrowth in pediatric renal transplant recipients. Pediatr Dent 1996;18:450-5.
21. Kilpatrick NM, Weintraub RG, Lucas JO, Shipp A, Byrt T, Wilkinson JL. Gingival overgrowth in pediatric heart and heart-lung transplant recipients. J Heart Lung Transplant 1997;16:1231-1237.
22. Lowry LY, Welbury RR, Seymour RA, Waterhouse PJ, Hamilton JR. Gingival overgrowth in paediatric cardiac transplant patients: A study of 19 patients aged between 2 and 16 years. Int J Paediatr Dent 1995;5:217-222.
23. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: A community-based study. J Periodontol 1999;70:63-67.
24. Nishikawa S, Nagata T, Morisaki I, Oka T, Ishida H. Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. J Periodontol 1996; 67:463-471.
25. Seymour RA, Heasman PA. Drugs and the periodontium. J Clin Periodontol 1988;15:1-16.
26. Seymour RA, Jacobs DJ. Cyclosporine and the gingival tissues. J Clin Periodontol 1992;19:1-11.
27. Sheehy EC, Roberts GJ, Beighton D, Obrien G. Oral health in children undergoing liver transplantation Int J Paediatr Dent 2000;10:109-119.
28. Daley TD, Wysocki GP, Day C. Clinical and pharmacologic correlations in cyclosporine-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1986;62: 417-421.
29. Seymour RA, Thomason JM, Ellis JS. Oral and dental problems in the organ transplant patient. Dent Update 1994;21:209-212.
30. Seymour RA, Preshaw PM, Thomason JM, Ellis JS, Steele JG. Cardiovascular diseases and periodontology. J Clin Periodontol 2003;30:279-292.
31. Ellis JS, Seymour RA, Thomason JM, Butler TJ, Idle JR. Periodontal variables affecting nifedipine sequestration in gingival crevicular fluid. J Periodontal Res 1995; 30:272-276.
32. Ellis JS, Seymour RA, Monkman SC, Idle JR. Gingival sequestration of nifedipine in nifedipine-induced gingival overgrowth. Lancet 1992;6:1382-1383.
33. Seymour RA, Ellis JS, Thomason JM, Monkman S, Idle JR. Amlodipine-induced gingival overgrowth. J Clin Periodontol 1994;21:281-283.
34. Margiotta V, Pizzo I, Pizzo G, Barbaro A. Cyclosporine- and nifedipine-induced gingival overgrowth in renal transplant patients: Correlations with periodontal and pharmacological parameters, and HLA-antigens. J Oral Pathol Med 1996;25:128-134.
35. O'Valle F, Mesa F, Aneiros J, et al. Gingival overgrowth induced by nifedipine and cyclosporine A. Clinical and morphometric study with image analysis. J Clin Periodontol 1995;22:591-597.
36. Thomason JM, Seymour RA, Ellis JS, et al. Iatrogenic gingival overgrowth in cardiac transplantation. J Periodontol 1995;66:742-746.
37. Wilson RF, Morel A, Smith D, et al. Contribution of individual drugs to gingival overgrowth in adult and juvenile renal transplant patients treated with multiple therapy. J Clin Periodontol 1998;25:457-464.
38. Somacarrera ML, Hernandez G, Acero J, Moskow BS. Factors related to the incidence and severity of cyclosporine-induced gingival overgrowth in transplant patients. A longitudinal study. J Periodontol 1994;65: 671-675.
39. Hassell TM, Page RC. The major metabolite of phenytoin (dilantin) induces gingival overgrowth in cats. J Periodontal Res 1978;13:280-282.
40. Thomason JM, Seymour RA, Ellis JS, et al. Determinants of gingival overgrowth severity in organ transplant patients. An examination of the role of HLA phenotype. J Clin Periodontol 1996;23:628-633.
41. Pernu HE, Pernu LM, Huttunen KR, Nieminen PA, Knuuttila ML. Gingival overgrowth among renal transplant recipients related to immunosuppressive medication and possible local background factors. J Periodontol 1992;63: 548-553.
42. Daley TD, Wysocki GP, Mamandras AH. Orthodontic therapy in the patient treated with cyclosporine. Am J Orthod Dentofac Orthop 1991;100:537-541.
43. Varga E, Lennon MA, Mair LH. Pre-transplant gingival hyperplasia predicts severe cyclosporine-induced gingival overgrowth in renal transplant patients. J Clin Periodontol 1998;25:225-230.
44. Hassell TM, Page RC, Narayanan AS, Cooper CG. Diphenylhydantoin (dilantin) gingival hyperplasia: Drug-induced abnormality of connective tissue. Proc Natl Acad Sci (USA) 1976;73:2909-2912.
45. Chang C, Werb Z. The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001;11:S37-S32.
46. Shikata H, Utsumi N, Shimojima T, Oda Y, Okada Y. Increased expression of type VI collagen genes in drug-induced gingival enlargement. FEBS Lett 1993;334:65-68.
47. Romanos GE, Strub JR, Bernimoulin JP. Immunohistochemical distribution of extracellular matrix proteins as a diagnostic parameter in healthy and diseased gingiva. J Periodontol 1993;64:110-119.
48. Pernu HE, Knuuttila ML, Huttunen KR, Tiilikainen AS. Drug-induced gingival overgrowth and class II major histocompatibility antigens. Transplantation 1994;57: 1811-1813.
49. Chincaglia GP, Forniti F, Cavallini R, Piva R, Calura G, del Senno L. Cyclosporine-A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med 1992;21:181-185.
50. Goultschin J, Shoshan S. Inhibition of collagen breakdown by diphenylhydantoin. Biochem Biophys Acta 1980;631:188-191.
51. Dill RE, Miller EK, Weil T, Lesley S, Farmer GR, Iacopino AM. Phenytoin increases gene expression for platelet-derived growth factor B chain in macrophages and monocytes. J Periodontol 1993;64:169-173.
52. Hassell TM, Gilbert GH. Phenytoin sensitivity of fibroblasts as the basis for susceptibility to gingival enlargement. Am J Pathol 1983;112:218-223.
53. Taylor B. Management of drug-induced gingival enlargement with orthodontic complications. Ann R Australas Coll Dent Surg 2000;15:150-154.
54. Church LF Jr, Brandt SK. Phenytoin-induced gingival overgrowth resulting in delayed eruption of the primary dentition. A case report. J Periodontol 1984;55:19-21.
55. Jorgenson RJ, Cocker ME. Variation in the inheritance and expression of gingival fibromatosis. J Periodontol 1974; 45:472-477.
56. Oikarinen K, Salo T, Kaar ML, Lahtela P, Altonen M. Hereditary gingival fibromatosis associated with growth hormone deficiency. Br J Oral Maxillofac Surg 1990;28: 335-359.
57. Bhowmick SK, Gidvani VK, Rettig KR. Hereditary gingival fibromatosis and growth retardation. Endocr Pract 2001;7:383-387.
58. Chodirker BN, Chudley AE, Toffler MA, Reed MH. Zimmerman-Laband syndrome and profound mental retardation. Am J Med Genet 1986;25:543-547.
59. Aldred MJ, Crawford PJ. Juvenile hyaline fibromatosis. Oral Surg Oral Med Oral Pathol 1987;63:71-77.
60. Winter GB, Simpkiss MJ. Hypertrichosis with hereditary gingival hyperplasia. Arch Dis Child 1974;49:394-399.
61. Joseph K, Guelmann M, Barak S. Hereditary gingival fibromatosis with distinct dental, skeletal and developmental abnormalities. Pediatr Dent 2002;24:253-256.
62. Ramer M, Marrone J, Stahl B, Burakoff R. Hereditary gingival fibromatosis: Identification, treatment, control. J Am Dent Assoc 1996;127:493-495.
63. Guevara-Sangines E, Villalobos A, Vega-Memije ME, Mosqueda-Taylor A, Canun-Serrano S. Congenital generalized terminal hypertrichosis with gingival hyperplasia. Ped Dermatol 2002;19:114-118.
64. Bozzo L, Machado MA, de Almeida OP, Lopes MA, Coletta RD. Hereditary gingival fibromatosis: Report of three cases. J Clin Pediatr Dent 2000;25:41-46.
65. Baptista IP. Hereditary gingival fibromatosis: A case report. J Clin Periodontol 2002;29:871-874.
66. Coletta RD, Almeida OP, Reynolds MA, Sauk JJ. Alteration in expression of MMP-1 and MMP-2 but not TIMP-1 and TIMP-2 in hereditary gingival fibromatosis is mediated by TGF-β1 autocrine stimulation. J Periodontal Res 1999;34:457-463.
67. Cuestas-Carnero R, Bornancini CA. Hereditary generalized gingival fibromatosis associated with hypertrichosis: Report of five cases in one family. J Oral Maxillofac Surg 1988;46:415-420.
68. Ramon Y, Berman W, Bubis JJ. Gingival fibromatosis combined with cherubism. Oral Surg Oral Med Oral Pathol 1967;24:435-448.
69. Bozzo L, Machado MA, de Almeida OP, Lopes MA, Coletta RD. Hereditary gingival fibromatosis: Report of three cases. J Clin Pediatr Dent 2000;25:41-46.
70. Kelekis-Cholakis A, Wiltshire WA, Birek C. Treatment and long-term follow-up with hereditary gingival fibromatosis: A case report. J Can Dent Assoc 2002;68: 290-294.
71. Tipton DA, Howell KJ, Dabbous MK. Increased proliferation, collagen, and fibronectin production by hereditary gingival fibromatosis fibroblasts. J Periodontol 1997; 68:524-530.
72. Gunhan O, Gardner DG, Bostanci H, Gunhan M. Familial gingival fibromatosis with unusual histologic findings. J Periodontol 1995;66:1008-1011.
73. McCulloch CAG, Knowles GC. Deficiencies in collagen phagocytosis by human fibroblasts in vitro: A mechanism for fibrosis? J Cell Physiol 1993;155:461-471.
74. Sodek J, Ferrier JM. Collagen remodelling in rat periodontal tissues: Compensation for precursor reutilization confirms rapid turnover of collagen. Coll Relat Res 1988;8: 11-21.
75. Ekisz O, Darimont F, Rompen EH. Diffuse but unilateral gingival enlargement associated with von Recklinghausen neurofibromatosis. J Clin Periodontol 2000;27: 361-365.
76. Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1-6.
77. Freedus MS, Doyle PK. Multiple neurofibromatosis with oral manifestations. J Oral Surg 1975;33:360-363.
78. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med 1981;305:1617-1627.
79. Reynolds RL, Pineda CA. Neurofibromatosis: Review and report of case J Am Dent Assoc 1988;117:735-737.
80. Clementi M, Barbujani G, Turolla L, Tenconi R. Neurofibromatosis-1: A maximum likelihood estimation of mutation rate. Hum Genet 1990;84:116-118.
81. Huson SM, Harper PS, Compston DAS. Von Recklinghausen neurofibromatosis. A clinical and population study in Southeast Wales. Brain 1988;111:1355-1381.
82. Fuller LC, Cox B, Gardner RJM. Prevalence of von Recklinghausen neurofibromatosis in Dunedin, New Zealand. Neurofibromatosis 1989;2:278-283.
83. Korf BR. Plexiform neurofibromas. Am J Med Genet 1999;89:31-37.
84. Preston FW, Walsh WS, Clarke TH. Cutaneous neurofibromatosis (von Recklinghausen's disease): Clinical manifestations and incidence of sarcoma in 61 male patients. Arch Surg 1952;64:813-827.
85. Cherrick HM, Eversole LR. Benign neural sheath neoplasm of the oral cavity. Report of 37 cases. Oral Surg Oral Med Oral Pathol 1971;32:900-909.
86. Pearson-Webb MA, Kaiser-Kupfer MI, Eldridge R. Eye findings in bilateral acoustic (central) neurofibromatosis: Association with present lens opacities and cataracts but absence of Lisch nodules. N Engl J Med 1986; 315:1553-1554.
87. Stokes RW. Neurofibromatosis: Review of the literature. J Am Osteopath Assoc 1986;86:49-52.
88. Kondoh T, Kamimura N, Tsuru A, Matsumoto T, Matsuzaka T, Moriuchi H. A case of Schinzel- Geidion syndrome complicated with progressive severe gingival hyperplasia and progressive brain atrophy. Pediatr Int 2001;43:181-184.
89. Melinkeri SR, Gupta RK, Dabagdhao S. A Sweet-like syndrome manifesting as gingival hyperplasia and myositis without cutaneous involvement. Ann Hematol 2002;81: 397-398.
90. Nikolatou-Galitis O, Papadaki T, Mashovi M, et al. Gingival overgrowth as the initial paraneoplastic manifestation of Hodgkin's lymphoma in a child. A case report. J Periodontol 2001;72:107-112.